ADPT vs NTRA vs CAI Stock Comparison

Adaptive Biotechnologies, Natera and Caris Life Sciences Prices as of Nov 13, 2026 Peers: Industry group
NTRA Natera, Inc.
$319.09 -19.2% 1M +59.0% 1Y
Market cap
$42.09B
P/E
–
Revenue (TTM)
$2.91B
Div. yield
–
Diagnostic Labs Healthcare
3 wins

Head to Head

9 decided of 12

Caris Life Sciences leads on 5 of the 12 questions below (Caris Life Sciences 5, Natera 3, Adaptive Biotechnologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADPTNTRACAILeader
Larger companyMarket capitalisation $4.50B $42.09B $6.06B NTRA
Cheaper on earningsLower P/E, profitable companies only -63.8x -255.5x 63.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 230.4x –
Faster revenue growthRevenue growth, trailing twelve months +17.9% +37.4% +61.5% CAI
More profitableNet margin, trailing twelve months -23.7% -5.7% 9.2% CAI
Better return on capitalReturn on invested capital — -9.9% 13.7% CAI
Less leveragedLower net debt / EBITDA — 5.6x -2.3x CAI
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +105.4% +59.0% -5.2% ADPT
Better 5-year returnAnnualised price return, 5 years -2.6%/yr +22.7%/yr — NTRA
Less volatileAnnualised volatility, 1 year 67.6% 52.1% 71.8% NTRA
Higher overall scoreMean of the five percentile scores vs peers 42/100 52/100 66/100 CAI

Percentile Scorecard

ADPTNTRACAI

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADPTNTRACAI
Valuation 12 #87 of 99 13 #86 of 99 25 #75 of 99
Growth 83 #16 of 89 80 #19 of 89 99 #2 of 89
Profitability 25 #69 of 92 35 #60 of 92 70 #28 of 92
Financial Health 70 #32 of 103 85 #16 of 103 81 #20 of 103
Shareholder Returns 21 #50 of 63 45 #35 of 63 55 #29 of 63
Overall 42 52 66
  • ADPT ranked among 103 companies in Healthcare Providers
  • NTRA ranked among 103 companies in Healthcare Providers
  • CAI ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADPTNTRACAISPY
1 month +13.3%-19.2%-23.8% -2.0%
3 months +17.4%+3.0%+5.7% -2.8%
6 months +126.3%+71.2%+58.4% +2.0%
Year to date +78.8%+39.3%-14.6% +10.6%
1 year +105.4%+59.0%-5.2% +12.2%
3 years +610.0%+512.2%— +68.1%
3 years, per year +92.3%+83.0%— +18.9%
5 years -12.6%+177.4%— +61.4%
5 years, per year -2.6%+22.7%— +10.1%
10 years —+2,761.8%— +248.5%
10 years, per year —+39.9%— +13.3%

Risk

MeasureADPTNTRACAISPY
Volatility, 1Y 67.6%52.1%71.8% 13.6%
Downside volatility, 1Y 62.9%53.1%74.4% 13.9%
Beta vs S&P 500, 1Y 1.571.291.92 1.00
Return / volatility, 1Y 1.561.13-0.07 0.90
Max drawdown, 5Y -92.8%-75.7%-63.0% -25.4%
From 52-week high -4.0%-26.8%-36.2% -3.2%
52-week high $30.26$436.00$36.14 $779.14
52-week low $12.41$182.65$14.55 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADPTNTRACAI
P/E now vs peer median -66.0xmedian 22.4x -279.0xmedian 22.4x 68.1xmedian 22.4x
P/S now vs peer median 15.7xmedian 1.3x 15.8xmedian 1.3x 6.3xmedian 1.3x
EV/EBITDA now vs peer median -132.7xmedian 14.2x -248.1xmedian 14.2x 37.5xmedian 14.2x
P/FCF now vs peer median -531.8xmedian 19.0x 877.9xmedian 19.0x 228.5xmedian 19.0x
P/B now vs peer median 25.5xmedian 2.6x 24.6xmedian 2.6x 10.3xmedian 2.6x
PEG now vs peer median -1.90median 0.84 -7.78median 0.84 —median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADPTNTRACAI
Revenue $298.01M $2.91B $1.05B
Gross profit $220.98M $1.84B $724.14M
Operating income -$48.21M -$260.42M $139.94M
Net income -$70.73M -$164.72M $96.06M
Free cash flow -$8.82M $52.47M $28.91M
R&D $83.18M $856.40M $129.36M
EPS (diluted) $-0.38 $-1.14 $0.33
Cash & equivalents $75.62M $1.10B $665.32M
Total debt – $80.30M $393.27M
Shares (diluted) 186.88M 144.07M 295.14M
Enterprise value $3.41B $37.72B $2.88B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADPTNTRACAI
P/E -66.0x -279.0x 68.1x
P/FCF -531.8x 877.9x 228.5x
P/Operating cash flow -1,097x 216.5x 78.7x
P/S 15.7x 15.8x 6.3x
P/B 25.5x 24.6x 10.3x
P/Tangible book 25.6x 30.4x 10.3x
EV/EBITDA -132.7x -248.1x 37.5x
EV/EBIT -91.1x -173.0x 44.5x
EV/Revenue 14.7x 15.5x 5.9x
EV/FCF -498.0x 858.4x 215.6x
EV/Operating cash flow -1,027x 211.7x 74.3x
PEG (3Y EPS CAGR) -1.90 -7.78 –

Growth

14 metrics
MetricADPTNTRACAI
Revenue growth (1Y) 17.9% 37.4% 61.5%
Revenue CAGR (3Y) 18.4% 43.3% –
Gross profit growth (1Y) 21.7% 41.1% 86.2%
Gross profit CAGR (3Y) 27.3% 68.2% –
Operating income growth (1Y) 38.3% 26.0% 274.2%
Operating income CAGR (3Y) 37.3% 19.7% –
Net income growth (1Y) 11.1% 46.7% 151.4%
Net income CAGR (3Y) 28.8% 30.9% –
EPS growth (1Y) 22.7% 49.3% 114.2%
EPS CAGR (3Y) 34.7% 35.9% –
Operating cash flow growth (1Y) 92.9% 9.5% 15,464%
Operating cash flow CAGR (3Y) 70.1% 40.7% –
Free cash flow growth (1Y) 86.0% -50.5% 306.4%
Free cash flow CAGR (3Y) 62.8% 29.4% –

Profitability

14 metrics
MetricADPTNTRACAI
Gross margin 74.2% 63.3% 69.1%
EBITDA margin -11.1% -6.2% 15.9%
Operating margin -16.2% -9.0% 13.4%
Pretax margin 5.1% -7.7% 9.3%
Net margin -23.7% -5.7% 9.2%
FCF margin -3.0% 1.8% 2.8%
Operating cash flow margin -1.4% 7.3% 8.0%
Return on equity -42.3% -8.9% 15.5%
Return on assets -10.7% -6.1% 7.7%
Return on invested capital – -9.9% 13.7%
Return on capital employed -8.6% -12.5% 12.9%
Asset turnover 0.5x 1.1x 0.8x
Cash conversion (OCF / net income) 0.1x -1.3x 0.9x
Stock comp / revenue 15.5% 13.6% 6.7%

Financial Health

11 metrics
MetricADPTNTRACAI
Debt / assets – 2.9% 31.3%
Debt / equity – 0.0x 0.6x
Net debt / EBITDA – 5.6x -2.3x
Debt / FCF – 1.5x 13.6x
Liabilities / assets 73.1% 32.0% 49.1%
Equity / assets 26.9% 68.0% 50.9%
Interest coverage -5.3x -70.8x 3.3x
Current ratio 4.0x 2.8x 6.7x
Quick ratio 3.7x 2.6x 5.7x
Cash ratio 3.0x 1.8x 4.8x
Altman Z-score 3.45 31.15 5.68

Shareholder Returns

7 metrics
MetricADPTNTRACAI
Dividend yield – – –
Net buyback yield -0.9% -0.1% 0.0%
Shareholder yield -0.9% -0.1% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADPTNTRACAI
Forward P/E – – 230.4xFY2026
EPS, next fiscal year $-0.42FY2026 $-1.62FY2026 $0.10FY2026
EPS growth, the year after – – +190.0%
Revenue, next fiscal year $297.43MFY2026 $3.16BFY2026 $1.07BFY2026
Revenue growth, next FY +7.4%FY2026 +36.9%FY2026 +31.4%FY2026
Revenue growth, the year after +32.5% +7.5% +22.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADPTNTRACAI
Held by institutions 97.2% 95.5% 52.0%
Institutions holding 301 850 246
Change in shares held, QoQ +2.5% +2.7% -6.3%
Institutions buying 160 515 174
Institutions selling 87 240 47
Buyers to sellers 1.84 2.15 3.70

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADPTNTRACAI
ADPT 1.00 0.53 0.42
NTRA 0.53 1.00 0.59
CAI 0.42 0.59 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ADPT, NTRA and CAI?

Natera (NTRA) is the largest by market capitalisation: Adaptive Biotechnologies (ADPT) $4.50B, Natera (NTRA) $42.09B, Caris Life Sciences (CAI) $6.06B.

Which company is growing faster?

Caris Life Sciences (CAI) grew revenue fastest over the trailing twelve months: Adaptive Biotechnologies (ADPT) +17.9%, Natera (NTRA) +37.4%, Caris Life Sciences (CAI) +61.5%.

Which company is more profitable?

Caris Life Sciences (CAI) has the highest net margin (Adaptive Biotechnologies (ADPT) -23.7%, Natera (NTRA) -5.7%, Caris Life Sciences (CAI) 9.2%). On return on invested capital, Caris Life Sciences (CAI) leads (Natera (NTRA) -9.9%, Caris Life Sciences (CAI) 13.7%).

Which stock has performed better?

Over the past year Adaptive Biotechnologies (ADPT) returned the most: Adaptive Biotechnologies (ADPT) +105.4%, Natera (NTRA) +59.0%, Caris Life Sciences (CAI) -5.2%. Over five years, Natera (NTRA) compounded fastest (Adaptive Biotechnologies (ADPT) -2.6%/yr, Natera (NTRA) +22.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Natera (NTRA) has been the steadiest (Adaptive Biotechnologies (ADPT) 67.6%, Natera (NTRA) 52.1%, Caris Life Sciences (CAI) 71.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ADPT, NTRA and CAI?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Caris Life Sciences (CAI) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.